Narvo Vexar/iStock via Getty Images
ImmunityBio (IBRX) actions added ~12% in pre-marketing on Wednesday after the Saudi Food and Drug Authority approved its top-selling immunotherapy, Anktiva, for certain bladder cancer patients.
According to the San Diego, California-based biotechnology company, the SFDA approval allows the company to
